Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. - Wikidata - wikimedia - TriplyDB

Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.

Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.

http://www.wikidata.org/entity/Q39593159

about

Radioresistance of Brain Tumors Emerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorder Molecular therapy of colorectal cancer: progress and future directions Novel delivery strategies for glioblastoma Will kinase inhibitors make it as glioblastoma drugs?In vitro models of cancer stem cells and clinical applications NETRIN-4 protects glioblastoma cells FROM temozolomide induced senescence Enhancing the efficacy of drug-loaded nanocarriers against brain tumors by targeted radiation therapy.Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma.Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma.Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Multiple signal pathways in obesity-associated cancer.Sequential dosing in chemosensitization: targeting the PI3K/Akt/mTOR pathway in neuroblastoma.Leveraging metabolomics to assess the next generation of temozolomide-based therapeutic approaches for glioblastomas The challenges and the promise of molecular targeted therapy in malignant gliomas.Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors Novel therapies in glioblastoma.An integrated method for reproducible and accurate image-guided stereotactic cranial irradiation of brain tumors using the small animal radiation research platform.Imp2 regulates GBM progression by activating IGF2/PI3K/Akt pathway.IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide Multi-parameter systematic strategies for predictive, preventive and personalised medicine in cancer.Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas.Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia.The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas.MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival.Long lasting MDM2/Translocator protein modulator: a new strategy for irreversible apoptosis of human glioblastoma cells.An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.mTOR Inhibition: From Aging to Autism and Beyond.Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.mTOR pathway in colorectal cancer: an update.Apoptosis therapy in cancer: the first single-molecule co-activating p53 and the translocator protein in glioblastoma.Bioluminescence imaging: progress and applications

P2860

Q26752579-E79A7CEC-4155-42A5-B0F0-30CBC54107CA Q26859114-0C861E2B-7352-4031-82B5-2C5EE6F8A518 Q27005764-68C0863E-38E6-410F-A0E1-F4D55400E7CB Q27006099-B6E4836B-C9E6-4398-A597-2AA1F2280A01 Q27012684-66FA09CD-C10E-4654-A671-7696C4495AE9 Q28076101-DD886830-8A1B-4E47-8216-B66D4A181671 Q28535039-926444E4-A5C0-4867-8B43-E6FEE0CB83CE Q30452421-B89EB0C2-A226-4D7C-B2CD-0BF17B96A49E Q30524134-F84DF34D-7E8C-43FB-A74A-219FE84CCDA1 Q33413997-DCA41E25-12F1-4211-BC4A-B592273DCEE8 Q33423176-D47C11C0-F05E-45A5-A015-B4BE53AB334A Q33591658-265CDCAF-0AED-4F80-A294-4359FA80B664 Q33607950-0A6B973B-53C4-4F20-9B45-02B788AAB139 Q33776641-C3D2DF8C-4DAC-4A19-8B2A-BF9CDEDC573D Q34193764-819EE945-AC3D-423E-9950-1D1EB527327A Q34221882-B00760FB-8F6F-42CE-8EE8-53B7AFDDA2E4 Q34260622-1EC531F0-E2E3-45A2-A37B-0ADE5827500D Q34307356-A2849501-CCE0-4B5E-A2AC-B2EE3001025C Q34633750-9EB0F98E-A440-4658-A4E2-E6190F7C17FF Q35082400-4619D446-3AF7-4A5E-83D7-46B2A995FA19 Q35171890-422A66D1-CB3C-4BE6-81C7-4F2C60F05EFC Q35214534-E1CBE8AE-6198-4099-A6D8-DA4F75BA75B6 Q35545648-372A381C-C184-4001-8E3D-A2287FBBFAB1 Q35864136-8BDBEDD2-B356-453B-9CD5-C5BC0152DD2D Q36199826-428EC6A2-F452-4050-9F7D-195DDED4403B Q36214062-BA94334D-BC42-42C8-9DC0-988C8B589C2A Q36545498-154CCDFD-8DA3-4E19-90C9-D8D0BFFCB3CF Q36588615-8E887FBE-D211-4F21-B50F-BE13C9CC7CFA Q36603152-706498AE-ABC2-41F8-B661-CFFD1DE7AB7F Q36673421-0C7FB143-6A96-4FD9-A47C-DC169586C818 Q36833480-CDB9254D-345E-4924-91FC-88371D7B86F3 Q36918102-01CD01A5-DCAB-45FD-B6B5-F25B81EBAA66 Q36946655-BB0F56BE-0152-4511-BDF4-9C49365AE1B4 Q37344059-852249E9-3140-4CA3-AD0F-779F0E86707F Q37350230-383FA144-E037-405F-967F-BE06909D8C83 Q37385781-50F15FA9-9DD2-41EF-A8DA-3BEFE185D6C3 Q37544152-EB4FE5E1-DEE1-4C11-A1AC-24A2B3D2AC20 Q37649634-D412F047-6DDA-4F91-B4AB-9DA07EA76226 Q37718142-36FB7DD3-54E2-4B1B-91A4-4661B22A37C9 Q37905334-E558C7F5-436B-43CD-8292-160B7FC49345

P2860

Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.

http://www.wikidata.org/entity/Q39593159

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Inhibition of PI3K/mTOR pathwa ...... ion therapy with temozolomide.

@en

Inhibition of PI3K/mTOR pathwa ...... ion therapy with temozolomide.

@nl

type

label

Inhibition of PI3K/mTOR pathwa ...... ion therapy with temozolomide.

@en

Inhibition of PI3K/mTOR pathwa ...... ion therapy with temozolomide.

@nl

prefLabel

Inhibition of PI3K/mTOR pathwa ...... ion therapy with temozolomide.

@en

Inhibition of PI3K/mTOR pathwa ...... ion therapy with temozolomide.

@nl

P1433

Q39593159-E399A51B-8AA1-4A6A-9241-5D8125779A51

P1476

Q39593159-4E7E863C-C242-45D4-85B9-84839E9CE1A9

P2093

Q39593159-6495FA88-1A89-414B-823E-74C073162096

Q39593159-6C140AB3-6E08-4560-BB8E-9188CB50FB4C

Q39593159-7CCA9370-8F7E-4C77-9B7E-5B578C22E4B5

Q39593159-91907C3F-14B2-4530-8FA0-D408FC2FA6E8

Q39593159-B3250B71-C4C3-4429-9772-345EF3BAE0D5

Q39593159-BA779D41-4D49-4AFC-959A-72C63F401697

Q39593159-D3FB489A-EB9F-4B39-97D1-C68961BA1814

Q39593159-D7D8CC14-599C-4556-B027-08A1787DA38D

Q39593159-DC595AF4-F1B1-44DC-B243-1CFE96625EF2

Q39593159-E69CFB95-5A85-4A1C-BF66-FF259DA70C3C

P2860

Q39593159-05A45E74-5E66-4C13-9C77-7232E54FD691

Q39593159-0AE4211E-4CBC-491E-B642-3E885F1A1D54

Q39593159-0B520AE1-EEA8-4524-A7A1-B080311C179A

Q39593159-0EAF61E9-B2BC-4353-BB7F-F4E5B67BBEAA

Q39593159-15A516B7-1348-4DE6-9BA7-2A68138E3DCA

Q39593159-1C215FF1-AC67-4987-BD2C-F4B16AD5796A

Q39593159-1F0BBA87-9AAC-4FA9-BA27-88E6E0A73573

Q39593159-3778C2A0-FFC9-47AC-ABDF-2680B5403837

Q39593159-3C624A7C-B615-418D-8CCC-C38ABB581D94

Q39593159-402ACF7C-3EC3-4F29-9E9E-1688BDBDC6EE

P304

Q39593159-C2FF822C-B42D-422B-8005-28BE221B470E

P31

Q39593159-511B3D10-60B6-44B6-9A4C-D962C1105C6B

P356

Q39593159-D655B646-4275-41F7-9755-C6B71691C270

P433

Q39593159-A16B9510-1C5C-4032-B4D6-E61F25D75402

P478

Q39593159-981C0366-66BF-4C30-8FC9-2A2E93FB1C40

P50

Q39593159-79C57ECE-89F4-45DF-916D-818421172783

P577

Q39593159-3B761E3F-AE60-4191-BA9C-913E6FA494D9

P5875

Q39593159-12565F08-3384-4671-B982-F3218D72AC44

P698

Q39593159-CF545F8B-C134-40F1-8E00-94431354DED6

P921

Q39593159-926631C1-C350-4E8A-B19F-735673E0AF8D

P932

Q39593159-DCC156DA-57D0-4A44-AA74-381EBEBC117E

P356

P1433

P1476

Inhibition of PI3K/mTOR pathwa ...... ion therapy with temozolomide.

@en

P2093

C David James

http://www.w3.org/2001/XMLSchema#string

Dana T Aftab

http://www.w3.org/2001/XMLSchema#string

Daphne A Haas-Kogan

http://www.w3.org/2001/XMLSchema#string

Gautam Prasad

http://www.w3.org/2001/XMLSchema#string

Mei-Yin Polley

http://www.w3.org/2001/XMLSchema#string

Michael D Prados

http://www.w3.org/2001/XMLSchema#string

Mitchel S Berger

http://www.w3.org/2001/XMLSchema#string

Sabine Mueller

http://www.w3.org/2001/XMLSchema#string

Theo Sottero

http://www.w3.org/2001/XMLSchema#string

Tomoko Ozawa

http://www.w3.org/2001/XMLSchema#string

P2860

Yes and PI3K bind CD95 to signal invasion of glioblastoma

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling

P304

384-392

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOQ193

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

William A Weiss

P577

2011-02-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49832343

http://www.w3.org/2001/XMLSchema#string

P698

21317208

http://www.w3.org/2001/XMLSchema#string

P921

P932

3064692

http://www.w3.org/2001/XMLSchema#string